These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
727 related articles for article (PubMed ID: 30739887)
1. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review. Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692 [TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916 [TBL] [Abstract][Full Text] [Related]
6. The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study. Kim TW; Hwang SW; Kim KO; Cha JM; Joo YE; Cho YS Oncology; 2023; 101(1):49-58. PubMed ID: 36191562 [TBL] [Abstract][Full Text] [Related]
7. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506 [TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095 [TBL] [Abstract][Full Text] [Related]
9. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444 [TBL] [Abstract][Full Text] [Related]
10. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889 [TBL] [Abstract][Full Text] [Related]
11. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. Popovici V; Budinska E; Bosman FT; Tejpar S; Roth AD; Delorenzi M BMC Cancer; 2013 Sep; 13():439. PubMed ID: 24073892 [TBL] [Abstract][Full Text] [Related]
12. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846 [TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575 [TBL] [Abstract][Full Text] [Related]
14. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459 [TBL] [Abstract][Full Text] [Related]
18. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668 [TBL] [Abstract][Full Text] [Related]
19. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
20. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]